Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
TORONTO, March 26, 2024 (GLOBE NEWSWIRE) — Further to the announcement by Psyence Group Inc (“Psyence” or the “Company“) (CSE:PSYG) of its plans for the strategic restructuring of its non-clinical business through a conditional M&A transaction (the “Transaction“), Psyence is pleased to announce that the conditions to implement the Transaction have been met and that the Transaction has closed.
Related news for (PSYGF)
- Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
- Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
- Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
- Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division